The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country.

While the shares retreated a bit (after a big increase the day before the announcement), we think this announcement represents a step in ... much cheaper sequencing than Illumina's existing ...

Illumina's new Global Health Access Initiative is a step forward to address these challenges. The program will provide discounted prices for a range of sequencing applications, including drug ...

Illumina employees have been showing their commitment to early cancer detection and advancing research and treatment by getting involved in the company’s recently concluded Steps Against Cancer ...

PerkinElmer’s model follows Complete Genomics, Illumina, and BGI (formerly known as Beijing Genomics Institute), wherein companies provide sequencing as a service rather than developing and ...

Illumina maintains that it can still maintain leadership in sequencing even as would-be rivals step up their activity in the space, potentially shrinking its market share as more rivals emerge ...

"We made a patterned flow cell using a more cost-efficient manufacturing process to help drive sequencing costs down. We've had these big step changes in the industry driven by Illumina.

Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2025 results , but sales fell by 1.4% year on year to $1.04 billion.